JP Morgan Chase’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $11.2M | Sell |
15,000
-26,000
| -63% | -$19.9M | ﹤0.01% | 2571 |
|
|
2025
Q4 | $31.6M | Hold |
41,000
| – | – | ﹤0.01% | 1682 |
|
|
2025
Q3 | $23.1M | Buy |
41,000
+37,900
| +1,223% | +$21.4M | ﹤0.01% | 1979 |
|
|
2025
Q2 | $1.63M | Sell |
3,100
-9,700
| -76% | -$5.41M | ﹤0.01% | 4064 |
|
|
2025
Q1 | $8.12M | Sell |
12,800
-24,400
| -66% | -$16.8M | ﹤0.01% | 2731 |
|
|
2024
Q4 | $26.5M | Sell |
37,200
-35,300
| -49% | -$29.6M | ﹤0.01% | 1779 |
|
|
2024
Q3 | $76.2M | Buy |
72,500
+27,500
| +61% | +$30.6M | 0.01% | 1087 |
|
|
2024
Q2 | $47.3M | Sell |
45,000
-19,900
| -31% | -$19.3M | ﹤0.01% | 1277 |
|
|
2024
Q1 | $62.5M | Sell |
64,900
-49,600
| -43% | -$47.2M | 0.01% | 1166 |
|
|
2023
Q4 | $101M | Buy |
114,500
+88,000
| +332% | +$72.5M | 0.01% | 880 |
|
|
2023
Q3 | $21.8M | Sell |
26,500
-40,600
| -61% | -$31.9M | ﹤0.01% | 1615 |
|
|
2023
Q2 | $48.2M | Buy |
67,100
+52,100
| +347% | +$40.2M | 0.01% | 1147 |
|
|
2023
Q1 | $12.3M | Buy |
15,000
+11,400
| +317% | +$8.6M | ﹤0.01% | 2089 |
|
|
2022
Q4 | $2.6M | Buy |
3,600
+500
| +16% | +$369K | ﹤0.01% | 3367 |
|
|
2022
Q3 | $2.13M | Hold |
3,100
| – | – | ﹤0.01% | 3413 |
|
|
2022
Q2 | $1.83M | Hold |
3,100
| – | – | ﹤0.01% | 3623 |
|
|
2022
Q1 | $2.17M | Buy |
+3,100
| New | +$1.96M | ﹤0.01% | 3689 |
|
|
2021
Q1 | – | Sell |
-22,500
| Closed | -$10.9M | – | 6299 |
|
|
2020
Q4 | $10.9M | Sell |
22,500
-500
| -2% | -$270K | ﹤0.01% | 2140 |
|
|
2020
Q3 | $13.2M | Buy |
23,000
+500
| +2% | +$303K | ﹤0.01% | 1810 |
|
|
2020
Q2 | $14M | Sell |
22,500
-14,000
| -38% | -$7.95M | ﹤0.01% | 1646 |
|
|
2020
Q1 | $17.8M | Sell |
36,500
-35,800
| -50% | -$14.8M | ﹤0.01% | 1335 |
|
|
2019
Q4 | $27.1M | Buy |
72,300
+13,700
| +23% | +$4.61M | 0.01% | 1349 |
|
|
2019
Q3 | $16.3M | Buy |
58,600
+9,200
| +19% | +$2.72M | ﹤0.01% | 1761 |
|
|
2019
Q2 | $15.3M | Buy |
49,400
+10,300
| +26% | +$3.43M | ﹤0.01% | 1761 |
|
|
2019
Q1 | $16.1M | Sell |
39,100
-200,500
| -84% | -$82.6M | ﹤0.01% | 1691 |
|
|
2018
Q4 | $89.5M | Buy |
239,600
+25,600
| +12% | +$9.37M | 0.02% | 659 |
|
|
2018
Q3 | $86.5M | Sell |
214,000
-17,000
| -7% | -$6.47M | 0.02% | 769 |
|
|
2018
Q2 | $79.7M | Buy |
231,000
+58,600
| +34% | +$18.3M | 0.02% | 738 |
|
|
2018
Q1 | $59.4M | Buy |
172,400
+64,900
| +60% | +$22.6M | 0.01% | 845 |
|
|
2017
Q4 | $40.4M | Buy |
107,500
+13,500
| +14% | +$5.47M | 0.01% | 1097 |
|
|
2017
Q3 | $40.9M | Buy |
94,000
+62,900
| +202% | +$29.9M | 0.01% | 1051 |
|
|
2017
Q2 | $15.3M | Buy |
31,100
+2,000
| +7% | +$875K | ﹤0.01% | 1641 |
|
|
2017
Q1 | $11.3M | Buy |
+29,100
| New | +$10.8M | ﹤0.01% | 1849 |
|
|
2016
Q1 | – | Sell |
-30,000
| Closed | -$16.3M | – | 4894 |
|
|
2015
Q4 | $16.3M | Hold |
30,000
| – | – | ﹤0.01% | 1484 |
|
|
2015
Q3 | $14M | Hold |
30,000
| – | – | ﹤0.01% | 1503 |
|
|
2015
Q2 | $15.3M | Hold |
30,000
| – | – | ﹤0.01% | 1594 |
|
|
2015
Q1 | $13.5M | Sell |
30,000
-15,000
| -33% | -$6.36M | ﹤0.01% | 1696 |
|
|
2014
Q4 | $18.5M | Hold |
45,000
| – | – | ﹤0.01% | 1537 |
|
|
2014
Q3 | $16.2M | Buy |
+45,000
| New | +$15.1M | ﹤0.01% | 1583 |
|
Other funds holding REGN
VCM
N
JP Morgan Chase's REGN Position: Q1 2026 in Review
JP Morgan Chase increased its Regeneron Pharmaceuticals (REGN) stake by 9.4% in Q1 2026, buying an estimated $285M and bringing the position to 4,311,806 shares worth $3.23B. The position accounts for 0.21% of the portfolio, ranked #106.
JP Morgan Chase first reported a position in REGN in Q2 2013 and has held it in 52 quarters since. The position peaked at $8.7B in Q2 2024. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.
- JP Morgan Chase held 4,311,806 shares of Regeneron Pharmaceuticals worth $3.23B as of Q1 2026.
- JP Morgan Chase bought 371,646 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $285M.
- Regeneron Pharmaceuticals made up 0.21% of JP Morgan Chase's portfolio in Q1 2026, its #106 holding.
- JP Morgan Chase first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
- JP Morgan Chase's Regeneron Pharmaceuticals position peaked at $8.7B in Q2 2024.
- 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.
Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.